We read with interest the article by Marie Lund and colleagues published in The Lancet Oncology investigating the association ...

The regulator approved the indication based on data showing Kisqali with an aromatase inhibitor improved invasive disease-free survival versus just an aromatase inhibitor.

Novartis’ Kisqali (ribociclib) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat a ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Novartis UK announced the Medicines and Healthcare products Regulatory Agency (MHRA) has authorised ribociclib for adjuvant ...

Patrick Payne, a Group 1-winning trainer, has been charged by Racing Victoria (RV) stewards after presenting a horse to the ...

Priya Hays, Hays Documentation Specialists, discusses innovations and advancements in the development of personalized cancer ...

Trainer to face charges for presenting horse to the races twice in 2024 with several banned substances in his system ...

such as tamoxifen or aromatase inhibitors for breast cancer or androgen ablation for prostate cancer. The effects of chemotherapy-associated cardiovascular toxicity and alterations in ...

Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings ...

Drug-related adverse events include hand ... Sorafenib might help overcome resistance to the aromatase inhibitors in patients with hormone receptor-positive MBC who have developed resistance ...

There were more grade 3/4 drug-related adverse events, however, coming in at 18.9% in the combination arm compared to 9.7% with Opdivo, and discontinuation rates were 14.6% and 6.7%, respectively.